Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature Jaccard A; Petit B; Girault S; Suarez F; Gressin R; Zini JM; Coiteux V; Larroche C; Devidas A; Thieblemont C; Gaulard P; Marin B; Gachard N; Bordessoule D; Hermine OAnn Oncol 2009[Jan]; 20 (1): 110-6BACKGROUND: Extranodal natural killer (NK)/T-cell lymphoma, nasal type, and aggressive NK-cell leukemia are highly aggressive diseases with a poor outcome. PATIENTS AND METHODS: We report a multicentric French retrospective study of 15 patients with relapsed, refractory, or disseminated disease, treated with L-asparaginase-containing regimens in seven French centers. Thirteen patients were in relapse and/or refractory and 10 patients were at stage IV. RESULTS: All but two of the patients had an objective response to L-asparaginase-based treatment. Seven patients reached complete remission and only two relapsed. CONCLUSION: These data, although retrospective, confirm the excellent activity of L-asparaginase-containing regimens in refractory extranodal NK/T-cell lymphoma and aggressive NK-cell leukemia. Therefore, L-asparaginase-based regimen should be considered as a salvage treatment, especially for patients with disseminated disease. First-line L-asparaginase combination therapy for extranodal NK/T-cell lymphoma and aggressive NK-cell leukemia should be tested in prospective trials.|Adult[MESH]|Aged[MESH]|Aged, 80 and over[MESH]|Antineoplastic Combined Chemotherapy Protocols/*therapeutic use[MESH]|Asparaginase/*administration & dosage[MESH]|Drug Resistance, Neoplasm/drug effects[MESH]|Female[MESH]|Humans[MESH]|Leukemia/*drug therapy/pathology[MESH]|Lymphoma, Extranodal NK-T-Cell/*drug therapy/pathology[MESH]|Male[MESH]|Middle Aged[MESH]|Recurrence[MESH]|Retrospective Studies[MESH]|Treatment Outcome[MESH]|Western World[MESH] |